Nuvaring and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Nuvaring (ethinyl estradiol; etonogestrel), especially for people who are female, 20-29 old, have been taking the drug for 1 - 2 years also take Mirena, and have Systemic lupus erythematosus.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Nuvaring. It is created by eHealthMe based on reports of 27,664 people who have side effects when taking Nuvaring from the FDA, and is updated regularly.

What is Nuvaring?

Nuvaring has active ingredients of ethinyl estradiol; etonogestrel. It is often used in birth control. eHealthMe is studying from 28,730 Nuvaring users. Check the latest studies of Nuvaring.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,327 drugs and 3,591 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

On Jul, 05, 2026

27,664 people reported to have side effects when taking Nuvaring.
Among them, 20 people (0.07%) have Agranulocytosis.

Among these 20 people:

How long have people been on Nuvaring when they have Agranulocytosis? *

What is the gender of people who have Agranulocytosis when taking Nuvaring? *

female: 93.75 %
male: 6.25 %

What is the age of people who have Agranulocytosis when taking Nuvaring? *

What are other drugs people take besides Nuvaring? *

Mirena: 4 people, 20.00%
Cialis: 3 people, 15.00%
Motrin: 3 people, 15.00%
Zofran: 2 people, 10.00%
Omega-3 Marine Triglycerides: 2 people, 10.00%
Fentanyl: 2 people, 10.00%
Tizanidine Hydrochloride: 2 people, 10.00%
Magnesium Sulfate: 2 people, 10.00%
Acetaminophen: 1 person, 5.00%
Depo-Provera: 1 person, 5.00%

What are other side effects people have besides Agranulocytosis? *

Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 11 people, 55.00%
Pulmonary Embolism (blockage of the main artery of the lung): 11 people, 55.00%
Fatigue (feeling of tiredness): 9 people, 45.00%
Anaemia (lack of blood): 7 people, 35.00%
Weight Increased: 6 people, 30.00%
Pvt: 6 people, 30.00%
Hypotension (abnormally low blood pressure): 5 people, 25.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 25.00%
Maternal Exposure Before Pregnancy (use of substance before pregnancy): 4 people, 20.00%
Leukopenia (less number of white blood cells in blood): 4 people, 20.00%

What are the existing conditions these people have? *

Vasculitis Gastrointestinal (inflammation of the blood vessel wall involving the gastrointestinal): 3 people, 15.00%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 3 people, 15.00%
Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 10.00%
Hepatitis C: 1 person, 5.00%
Heavy Or Prolong Menstrual Bleeding: 1 person, 5.00%
Hair Loss: 1 person, 5.00%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Nuvaring and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nuvaring:

Nuvaring (28,730 reports)

Agranulocytosis treatments and more:

Agranulocytosis (213,267 reports)

How severe was Agranulocytosis and when was it recovered:

Agranulocytosis in Nuvaring

Expand to all the drugs that have ingredients of ethinyl estradiol; etonogestrel:

Agranulocytosis and drugs with ingredients of ethinyl estradiol; etonogestrel (18 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Nuvaring:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,327 drugs)

Browse all the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,591 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; etonogestrel (the active ingredients of Nuvaring) and Nuvaring (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.